News archive

New Advances for Warmwater Aquaculture - Symposium 2007



Fish producers are moving toward intensified production in response to world demand for aquaculture products at the same time that consumer demand for safe, nutritious food is rising. Intense production can increase the risk for disease, however, and may require management changes.

Intervet/Schering-Plough Animal Health is committed to helping fish farmers meet these challenges. Toward this end, we hosted New Advances in Warmwater Aquaculture, a seminar held in San Antonio, Texas, in conjunction with the 2007 World Aquaculture Society meeting.

The daylong meeting, attended by fish farmers and specialists from Latin America, featured the latest scientific findings relative to managing disease in tilapia, shrimp and other warmwater species. The articles in this publication summarize key messages from those presentations.

Our thanks go to the speakers, who each gave meaningful, practical presentations and contributed to lively discussions with the audience during question and answer sessions.

Intervet/Schering-Plough Animal Health

Hank Behrend
Species Head
Global Aquatic Animal Health
Intervet/Schering-Plough Animal Health

Management is key to disease control as tilapia producers intensify production

Management practices are key to maintaining and improving the health of intensively produced tilapia, said Dr. Gina Conroy of Pharma Fish, Venezuela.


Studies demonstrate AQUAFLOR® (florfenicol) efficacy for control of S. iniae mortality in tilapia

A series of controlled studies demonstrates that AQUAFLOR® (florfenicol) effectively controls mortality due to Streptococcus iniae in Nile tilapia, according to Dr. Pat Gaunt, of Mississippi State University College of Veterinary Medicine and a veterinary toxicologist.

AQUAFLOR® offers tilapia producers novel tool for fighting bacterial infections without prolonged withdrawal

Recent research indicates that AQUAFLOR® (florfenicol) treatment of tilapia does not require a prolonged withdrawal period, enabling producers to better control bacterial infections in fish nearing market weight, according to Dr. Lou Crouch of the Schering-Plough Research Institute.


Validated assay shows that AQUAFLOR® remains stable in floating or sinking pelleted feed for catfish, salmonids

Studies have demonstrated that AQUAFLOR® (florfenicol) remains stable in both floating and sinking pelleted feed for catfish and freshwater-reared salmonids, providing producers with a reliable method of controlling bacterial disease and preventing devastating losses, said John Hayes, of Schering-Plough Research Institute.

Study shows that AQUAFLOR® reduces mortality from NHP-B infection in shrimp

Using AQUAFLOR® (florfenicol) at 5 mg/kg resulted in fewer lesions and significantly decreased mortality compared to oxytetracycline in shrimp infected with necrotizing hepatopancreatitis (NHP-B), reported Dr. Maria Morales of the Research Center for Food and Development (CIAD), Mexico.


AQUAVAC™ GARVETIL™ vaccine safely reduces streptococcosis mortality in tilapia

A large-scale field trial demonstrated that mortality from streptococcosis in tilapia can be significantly reduced with a two-step vaccination program consisting of AQUAVAC™ GARVETIL™ and AQUAVAC™ GARVETIL™ ORAL, said Dr. Mario Aguirre, of Intervet/Schering-Plough Animal Health, Venezuela.

AQUAVAC™ ERGOSAN™ in rainbow trout initiates improved vaccine response, stress tolerance and weight

The immunomodulator AQUAVAC™ ERGOSAN™ improved tolerance to rearing conditions and heat stress and boosted vaccine response in a study carried out on rainbow trout, as reported by Dr. Oliana Carnevali, of the department of Marine Science at the Universita Politecnica delle Marche, Ancona, Italy.